chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Received the typhoid vaccine on 26 May 1982. He was seen in the clinic the following day for a reaction to typhoid with a temperature of 100.6; diagnosed with a serum reaction and ordered bed rest. He was seen for follow up and repeat CBC on 01 Jun 82 and was noted to have stomatitis. On 02 Jun his stomatitis improved with MAALOX and his CBC was returning to normal. He was seen again on 16 Jun 82 with a three day history of abdominal pain and bloody diarrhea. He returned to clinic on 17 Jun and was admitted for five days with an initial impression of Ulcerative Colitis. He was readmitted again on 02 July 82 for increased symptoms following a Barium enema. He was discharged on 20 Aug 82. During this hospitalization he was treated for toxic megacolon requiring hyperalimentation and six blood transfusions. In Nov 1984 he required a total colectomy with an ileostomy. In 1994 he was diagnosed with Crohn's disease and currently remains under treatment. Symptoms: Diarrhea, Abdominal Pain, Fever.  8/18/09 Hospital and Medical records received DOS 5/27 to 7/29/2008.  Inpatient DOS 6/17/82 to 6/22/82. Assessment: Ulcerative colitis.  Patient presented with 4 day history of cramp lower abdominal pains followed by diarrhea. Blood in bowel movments.  Outpatient DOS 7/2/09 to 8/20/82 Assessment: Probable Salmonellosis. Patient presents with episodes of high fever, chills, sweats.  Inpatient DOS 2/7/82 to 8/20/82. Assessment: Toxic megacolon secondary to severe ulcerative colitis with universal involvement of the colon. Patient presents with 5 days of blood diarrhea, developed fever. Abdominal tender with some enlargement. TPN. Calcium and magnesium deficiency.  Inpatient DOS 11/9/84 - 12/6/84. Assessment: Severe Ulcerative Colitis. Total colectomy. Ileostomy. Surgical Consult DOS 12/13/84. Assessment: Severe exacerbation of ulcerative colitis. Inpatient DOS 1/16/85 to 1/26/85. Closure of loop ileostomy. Drug sensitivity to Flagyl. Inpatient DOS 4/19/85 to 5/3/85. Assessment: Diarrhea and ulcerative colitis, chronic rectal pain, history of anemia. Laparotomy and creation of end ileostomy. Inpatient DOS 11/30/94 to 12/16/94. Assessment: Abdominal pain secondary to intraabdominal adhesions. Patient presents with intermittent episodes of bloating and right lower quadrant discomfort. Exploratory laparotomy and lysis of adhesions. Surgery and surgical pathology reports DOS 7/28/2008. Assessment Crohn's enteritis with distal ileal stricture. Exploratory laparotomy with lysis of adhesions. Complex reconstruction of Brooke ileostony with segmental ileal resection.
I did not have a reaction to the vaccine. I started not feeling well on 12/30/2022 with dizziness and so tired. From that point I started feeling worse. I tested positive for COVID-19 on 01/01/2023. I contacted my provider via telehealth, and I was advised I was not a candidate for Paxlovid. They did provide three prescriptions to help with my symptoms. As of today, I feel find without any lingering symptoms.
RN inserted needle into deltoid, needle automatically retracted and leaked vaccine on arm. Unknown how much if any vaccine was injected into arm.
The day after the vaccine i woke up with severe headache and had a severe headache for 3 weeks where taking medication on a daily basis every 4 hours. Severe headache is better but still am having daily headaches.  3 days after the vaccine i woke up in the middle of the night with severe Tachycardia  and 3 weeks from the vaccine i got a case of shingles on my back that had to be treated.
Following day, numbness in rt. arm and hand..followed by blister type sores in rt hand, thumb, index finger..elbow.. numerous breakout on arm..plus numerous breakouts at point of injection...horrendous pain, unbearable pain..Dr. appointment 7/21/2010 for prescriptions for pain.
A few hours after injection, experienced fatigue, muscle aches, joint aches and runny nose. Took Tylenol and seemed to help. Some trouble sleeping. Next morning still experiencing fatigue, muscle aches, joint aches and runny nose. Took more Tylenol, by mid-day felt better but by about 4pm fatigue, aches returned and also slight head ache.
Approx. 5 hours after vaccination, developed swelling around eyes & earlobes, eyes irritated. To quick care facility, given x2 injections. Next am, hives around waistline, itching, nose swelled. Went to local MD, given x2 injections & Predisone and Allegra Rx's.
Red swollen injection site. Approx 6x6 cm. Fever of 101 (may also have a viral illness and has abd. pain).
This spontaneous report was received from a pharmacist concerning a female patient of unknown age. Medical history and concurrent conditions were not reported. On an unknown date, the patient was vaccinated with a dose of ZOSTAVAX (dose, dose number and route were not reported) lot # K009198, expiration date 27-SEP-2015. Co-suspect and concomitant therapies were not reported. Pharmacist reported that on an unknown date, patient experienced a rash around the injection site after receiving ZOSTAVAX. At the time of the report patient's rash recovered 2 days later after injection. Patient did not received treatment or sought medical attention for the adverse event. Additional information has been requested.
Vertigo/Dizziness - moderate -severe dizzy for 12 hours, currently mild dizziness 24 hours later Was advised it should clear up but if not to notify doctor
pt recv vax 8JUN95 & 11 days p/vax pt began GBS;pt suffered leg cramps, h/a & elevated temp;fever, chills, vomiting, diarrhea, h/a, numbness in fingers & toes;28JUN vision was blurred & legs were weak;became paralyzed;dx GBS;no coordination
About 10 seconds after receiving the flu and Gardasil 9 vaccines, the patient had a syncopal episode. She was seated on the exam table for the vaccines and during the syncopal episode, she fell forward off the exam able and onto the floor. She landed on her face and the front of her body. She was coherent 5 seconds after the event and could state her name and recognized where she was in the doctor's office. After the fall, she complained of pain on her chin, in her mouth and a headache. She had a deep 2 cm laceration on her chin. The wound was cleaned and gauze was applied. I Inspected her mouth but saw no bleeding or teeth abnormalities. After 15 min of monitoring, she was sent to the ER for further evaluation.
1 1/2hr p/vax pt woke up dizzy & felt was going to  pass out;pt husband said pt look like a ghost;pt had lump in throat;pt kept repeating I am going to die;husband called 911;pt felt jittery & hyper & couldn't get back to sleep;poss low BP;
Pt c/o "joint" pain to (L) arm (shoulder, elbow finger) states some redness to (L) shoulder, zero redness/swelling at injection site.
Swelling and redness on left deltoid area 2 days post immunization. Warm compress arm movement to affected site with Motrin PRN.
flu-like symptoms; Appetite lost; diarrhea; rash; Myalgia; vomiting; fever; headache; chills; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a nurse and describes the occurrence of INFLUENZA LIKE ILLNESS (flu-like symptoms), DECREASED APPETITE (Appetite lost), DIARRHOEA (diarrhea), RASH (rash) and MYALGIA (Myalgia) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INFLUENZA LIKE ILLNESS (flu-like symptoms), DECREASED APPETITE (Appetite lost), DIARRHOEA (diarrhea), RASH (rash), MYALGIA (Myalgia), VOMITING (vomiting), PYREXIA (fever), HEADACHE (headache) and CHILLS (chills). At the time of the report, INFLUENZA LIKE ILLNESS (flu-like symptoms), DECREASED APPETITE (Appetite lost), DIARRHOEA (diarrhea), RASH (rash), MYALGIA (Myalgia), VOMITING (vomiting), PYREXIA (fever), HEADACHE (headache) and CHILLS (chills) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.
Patient called to say the night after the vaccine their arm had red blotches in the upper part. Said there was no rash or hives all over the body, it was just confined to the upper arm.
Patient presented ~2 weeks after 2nd pfizer vaccine with chest pain and tachycardia diagnosed with myopericarditis course complicated by pericardial effusion and hypotension which improved prior to discharge.
This spontaneous report was received from a nurse referring to unspecified number of patents of unknown age and gender. No information regarding patients' medical history, concurrent conditions and concomitant medications were provided. On an unknown dates starting on or after 02-JUL-2016, the patients were vaccinated with improperly stored doses of VAQTA (dose, route, lot # and expiry date not reported). The vaccine was exposed to temperature of 32.4 degree Fahrenheit for 95 hour. No previous temperature excursion and no adverse effects were reported. The call was not due to data logger. This is one of several reports received from the same reporter. Additional information has been requested
PATIENT HAD NO ADVERSE REACTION TO THIS VACCINE. SHE WAS ONLY 15 YEARS OF AGE AT THE TIME OF VACCINE. PATIENT RECEIVED THIS VACCINE DUE TO HER MEDICAL CONDITION OF HAVING ASTHMA.
Patient experienced severe chills and flu-like symptoms without fever. Rash expanding from injection site to elbow, injection site became a hard welt. Rash was and still is extremely itchy but is getting better. Flu-like symptoms have since resolved but lasted for about 2 days
Onset was 10 min post vaccination.  Symptoms experienced over an hour, in this order. Went to the ED. Some still continuing within 14 hrs past time of shot.  Severe headache. * same night Dizziness and lightheaded. * same night Nauseous  Clammy  Cheeks flushed Itchy  Chills  Short of breath / slight wheezing * same night Fatigue * same night
Fever of 102-103 degrees, muscle aches and all over body pains, chills, delirious, fatigue, headache/migraine, light sensitivity.
mom discovered about 4:00 on 7APR99 that child arm was red & feverish from inj site down to elbow;child c/o h/a & seemed fatigued but has not noticed any fever;apply cold compresses & given APAP;
Silver dime size hard red spot at injection site; Injection site hot to touch; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE ERYTHEMA (Silver dime size hard red spot at injection site) and VACCINATION SITE PAIN (Injection site hot to touch) in a 52-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 042L20A and 051k02A) for COVID-19 vaccination.     No Medical History information was reported.   On 05-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 02-Feb-2021, the patient experienced VACCINATION SITE ERYTHEMA (Silver dime size hard red spot at injection site) and VACCINATION SITE PAIN (Injection site hot to touch). At the time of the report, VACCINATION SITE ERYTHEMA (Silver dime size hard red spot at injection site) and VACCINATION SITE PAIN (Injection site hot to touch) outcome was unknown.            Treatment information included using ice on the area.
invalid dose: pediatrics; This spontaneous case was reported by a physician and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (invalid dose: pediatrics) in a 17-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 040A21A and 019B21A) for COVID-19 vaccination.     Concomitant products included DIENOGEST, ETHINYLESTRADIOL (LARISSA) for Birth control.   On 12-Mar-2021 at 4:50 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Apr-2021 at 1:03 PM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 12-Mar-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (invalid dose: pediatrics). On 12-Mar-2021, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (invalid dose: pediatrics) had resolved. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.    No treatment medication details was reported.   Most recent FOLLOW-UP information incorporated above includes: On 15-Jul-2021: Follow-up includes Concomitant medication was added. 2nd dose information was provided.
Woke up with redness, inflammation, and itching at the injection site. This was quite severe for 2 days and resolved to a low level of irritation. Shortly after this occurred, developed hives on both ankles.
Patient received Pfizer COVID vaccine on 8/11/21 (lot # FC3180), 9/1/21 (lot # FF2588), and 4/5/22 (lot # FM0698). There was a recent outbreak at patient's skilled nursing facility. On 4/14/22, patient admitted to our CCU with septic shock secondary to cellulitis/infected wounds lower extremity, UTI, and COVID-pneumonia (patient also tested positive for COVID during admission). Patient transferred to med/surg unit on 4/16/22. As of today 4/19/22, patient is still admitted in med/surg unit due to septic shock secondary to infected right lower extremity wounds with cellulitis. The COVID-19 infection has been relatively asymptomatic during hospitalization so far.
Pt was complaining of "throat swelling" and complaint of metallic taste in mouth. Zyrtec given.
Big toe was irritated and sore sore arm Bi toe was inflamed and felt like gout
Dose administered after more than 1 temperature excursions during a period of 33 weeks on 2021; Dose administered after more than 1 temperature excursions during a period of 33 weeks on 2021; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Dose administered after more than 1 temperature excursions during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Dose administered after more than 1 temperature excursions during a period of 33 weeks on 2021) in a 73-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 019B21A and 014M20A) for COVID-19 vaccination.     No Medical History information was reported.   On 28-Feb-2021 at 10:15 AM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 28-Mar-2021 at 10:26 AM, received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to .5 milliliter. On 28-Mar-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Dose administered after more than 1 temperature excursions during a period of 33 weeks on 2021). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Dose administered after more than 1 temperature excursions during a period of 33 weeks on 2021). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Dose administered after more than 1 temperature excursions during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Dose administered after more than 1 temperature excursions during a period of 33 weeks on 2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Patient age was reported age 73.19 during 28-Mar-2021 administration and 73.11 during 28-Feb-2021 administration.  No concomitant medication was reported by reporter.  Vials were in cooler storage and were not in frozen storage during high-pace COVID-19 vaccination at around 2021.  It was reported that each time a vial was put into a cooler, sometimes there was a period of time of 1 hour or 1 hour and a half approximately, when temperature data logger registered a temperature of 34 or 35 degree Fahrenheit. Temperature recordings were taken using a  traceable temperature monitor at every hour. Vials were moved to fridge on 23-Mar-2021 (Lot: 019B21A), 24-Feb-2021 (Lot: 014M20A) and moved to clinic on 27-Mar-2021 (Lot: 019B21A), 27-Feb-2021 (Lot: 014M20A). Vials were punctured right before administration. Vials best before use date were 22-Apr-2021 (Lot: 019B21A) and 26-Mar-2021 (Lot: 014M20A). Vials were undergone temperature excursion on 10:00 AM with 35 degree Fahrenheit (Lot: 019B21A) and 09:00 AM & 13:00 PM with 27 and 26 degree Fahrenheit (Lot: 014M20A). After administration, the vial was returned to the freezer/refrigerator, or maintained at room temperature.  No treatment medication was reported by reporter.
Patient was hospitalized due to breakthrough COVID-19 infection. Patient received 2nd dose in series on 11/09/2021. Patient was hospitalized from 12/23/21 to 12/26/21. Below is copied from discharge summary:   Hospital Course:  Patient s is a 42-yo female with PMH of migraines who presented to the ED with CC of generalied body aches and weakness, headache, chills and decreased appetite. She recently returned from a trip to a Country. She was diagnosed with covid 2 days prior to admission. She also reported she did not take malaria prophylaxis and was concerned for possible malaria infection.  Labs in the ED significant for thrombocytopenia with a platelet count of 54.  Otherwise no leukocytosis.  She had a mild fever of 100.2.  Oxygen saturation was greater than 92 percent on room air and therefore no benefit of IV steroids or remdesivir was deemed to be had.  Patient was admitted to the hospital and started on IV fluids and malaria antigen was checked which was positive.  Infectious Disease was consulted and recommended 3 days of Malarone.  The Paris a tenia was repeated and down to 0.01 from a prior value of 0.17 percent.  She remained asymptomatic from the COVID standpoint in terms of her oxygenation and respiratory symptoms.  She was eating more and did not have any further nausea or vomiting.  She was seen by PT and OT and cleared for discharge home. Thrombocytopenia resolved prior to d/c and labs otherwise stable. She was afebrile.  Patient is discharged in stable condition with stable vital signs. All questions rearding hospital course and plan of care after discharge have been answered to satisfaction. Prescriptions for medications needed to be taken after discharge have been given to patient. Patient has been instructed to follow up with PCP, within the next 7 days after discharge. Patient verbalizes understanding all given instructions and has no further doubts regarding discharge.
This spontaneous report was received from a patient of unknown age (adult) reporting on himself. The patient's medical history included recurrent herpes like inflammation in his mouth. The patient's historical drug included L-lysine taken for recurrent herpes like inflammation in mouth. Approximately on an unknown date in 2013, reported as last year, the patient was vaccinated with ZOSTAVAX (strength, dose, route of administration, site of administration and lot number were not reported). There were no concomitant medications reported. The patient reported that for most of his adult life, he had had problem with recurrent herpes like inflammation in his mouth which began with him biting his cheek or some similar injury. Within days, the patient would have an extremely painful inflammation that would last 6-10 days. Taking L-lysine helped ameliorate the symptoms, but did not prevent them. On an unknown date, since his ZOSTAVAX vaccination the patient did not have a flare up and reported that this might be a potential off label use of the vaccine. The patient also felt that thought the patient never had a cold sore, the vaccine might be helpful with them as well. The patient stated that it's just an observation of his, but it might be something worth looking into. There was no product quality complaint involved. It was unspecified whether the patient had sought any medical attention. The outcome and causality were unknown. Additional information has been requested.
no adverse effects reported; patient was vaccinated with improperly stored MMR II; This spontaneous report has been received from a medical assistant, concerning a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant medications were not provided.  On 02-MAY-2019,  the patient was vaccinated with improperly stored dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II) (albumin status rHA) one dose, lot # R024906 with expiration date 30-AUG-2020 (frequency, route and anatomical location were not provided) which was reconstituted with sterile diluent (dose, frequency, route, lot number and expiration date were not provided) for prophylaxis. No adverse effects reported.  The temperature and time frame were unknown by reporter. There was previously temperature excursions and digital data logger was involved.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-1906USA011469: US-009507513-1907USA010301: US-009507513-1907USA010302: US-009507513-1907USA010303: US-009507513-1907USA010304: US-009507513-1907USA010305: US-009507513-1907USA010306: US-009507513-1907USA010307: US-009507513-1907USA010308: US-009507513-1907USA010309: US-009507513-1907USA010310: US-009507513-1907USA010311: US-009507513-1907USA010312: US-009507513-1907USA010313: US-009507513-1907USA010314: US-009507513-1907USA010315: US-009507513-1907USA010316: US-009507513-1907USA010317: US-009507513-1907USA010318: US-009507513-1907USA010319: US-009507513-1907USA010320: US-009507513-1907USA010321: US-009507513-1907USA010322: US-009507513-1907USA010323: US-009507513-1907USA010324: US-009507513-1907USA010325: US-009507513-1907USA010326: US-009507513-1907USA010327: US-009507513-1907USA010328: US-009507513-1907USA010329: US-009507513-1907USA010330: US-009507513-1907USA010331: US-009507513-1907USA010332: US-009507513-1907USA010333: US-009507513-1907USA010334: US-009507513-1907USA010335: US-009507513-1907USA010336: US-009507513-1907USA010337: US-009507513-1907USA010338: US-009507513-1907USA010339: US-009507513-1907USA010340: US-009507513-1907USA010341: US-009507513-1907USA010342: US-009507513-1907USA010343: US-009507513-1907USA010344: US-009507513-1907USA010345: US-009507513-1907USA010346: US-009507513-1907USA010347: US-009507513-1907USA010348: US-009507513-1907USA010349: US-009507513-1907USA010350: US-009507513-1907USA010351: US-009507513-1907USA010352: US-009507513-1907USA010353: US-009507513-1907USA010354: US-009507513-1907USA010355: US-009507513-1907USA010356: US-009507513-1907USA010357: US-009507513-1907USA010358: US-009507513-1907USA010359: US-009507513-1907USA010360: US-009507513-1907USA010361: US-009507513-1907USA010362: US-009507513-1907USA010363: US-009507513-1907USA010365: US-009507513-1907USA010366: US-009507513-1907USA010367: US-009507513-1907USA010368: US-009507513-1907USA010369: US-009507513-1907USA010370: US-009507513-1907USA010371: US-009507513-1907USA010372: US-009507513-1907USA010373:
Pt immunized 8/22. No symptoms for about 24 hours. Pt with redness and swelling on (L) deltoid at about 24 hours (8/23).
Night chills 12 hours after shot.  Red lesion one day after shot. Red lesion remains two days after shot.
right arm is warm to touch and slightly tender but is improving from yesterday. No signs or suspicion of infection, reaction inferior to and distant from the injection site. Will use NSAIDS, Benadryl and cold compresses. Pt advised to call if no improvement.
Nauseous, vomiting, body aches, cold and hot sweats, fever, headache, weakness, abdominal pain, can?t keep any food down, just keep vomiting.